| 摘要 |
The present invention provides an animal model that can provide information on the effectiveness of postsurgical immunotherapies for recurrence of metastatic disease. In a specific embodiment, this tumor model used mice from which the primary 410.4 mammary carcinoma was surgically excised to assess the therapeutic potential of low-dose cyclophosphamide (CY) followed by vaccination with DNP-modified, gamma-irradiated, autologous tumor cells admixed with BCG compared to mice receiving low-dose CY followed by vaccination with unmodified, gamma-irradiated, autologous tumor cells admixed with BCG, or mice treated with PBS (control group). In this model, therapeutic benefits offered by DNP-modified, gamma-irradiated, autologous tumor cell vaccine (preceded by low-dose CY) were abrogated completely upon depletion of CD8+ T-cells, and was improved when the mice were pretreated with a single dose of DNP-modified, gamma-irradiated, autologous tumor cells (without BCG) prior to the low-dose CY treatment, and then subjected to vaccination with DNP-modified, gamma-irradiated, autologous tumor cells admixed with BCG.
|
